Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US6350860B1 · kind B1 · utility
35Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2000 |
| Grant date | Feb 26, 2002 |
| Priority date | — |
| Expiry date | Feb 14, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.